BIO vs BRKR

For growth investors, Bruker Corporation (BRKR) is the stronger pick with 2.

1% revenue growth year-over-year, versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 3x trailing P/E (25. 2x forward), making it the more compelling value choice. Analysts rate Bio-Rad Laboratories, Inc. (BIO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Bruker Corporation is actually cheaper at 20.

0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Bruker Corporation (BRKR) delivered a total return of -36.

6%, compared to -57. 0% for Bio-Rad Laboratories, Inc. (BIO). Over 10 years, the gap is even starker: BIO returned +82. 9% versus BRKR's +59. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 92β versus Bruker Corporation's 1. 59β — meaning BRKR is approximately 72% more volatile than BIO relative to the S&P 500. On balance sheet safety, Bio-Rad Laboratories, Inc. (BIO) carries a lower debt/equity ratio of 21% versus 81% for Bruker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bruker Corporation (BRKR) is pulling ahead at 2.

1% versus 0. 7% for Bio-Rad Laboratories, Inc. (BIO). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, BRKR leads at 10. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -0. 3% for Bruker Corporation — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIO leads at 10. 5% versus 6. 9% for BRKR. At the gross margin level — before operating expenses — BIO leads at 52. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bruker Corporation (BRKR) trades at 20.

0x forward P/E versus 25. 2x for Bio-Rad Laboratories, Inc. — 5. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BRKR: 23. 2% to $52. 13.

In this comparison, BRKR (0.

4% yield) pays a dividend. BIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Rad Laboratories, Inc.

(BIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92)). Bruker Corporation (BRKR) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BIO: +82. 9%, BRKR: +59. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BIO is a small-cap deep-value stock; BRKR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.